The drug is active against Human Endogenous Retroviruses (HERVs) and possibly Epstein–Barr virus, which have been suggested in the pathogenesis of relapsing-remitting MS.
The drug targets Human Endogenous Retroviruses (HERVs) and possibly Epstein–Barr virus, which have been implicated in the pathogenesis of relapsing-remitting MS.